Department of Clinical Oncology, Leiden University Medical Center, 2333 ZA Leiden, Netherlands.
J Exp Med. 2010 Jan 18;207(1):207-21. doi: 10.1084/jem.20091429. Epub 2009 Dec 28.
The nonclassical major histocompatibility complex (MHC) Qa-1b accommodates monomorphic leader peptides and functions as a ligand for germ line receptors CD94/NKG2, which are expressed by natural killer cells and CD8+ T cells. We here describe that the conserved peptides are replaced by a novel peptide repertoire of surprising diversity as a result of impairments in the antigen-processing pathway. This novel peptide repertoire represents immunogenic neoantigens for CD8+ T cells, as we found that these Qa-1b-restricted T cells dominantly participated in the response to tumors with processing deficiencies. A surprisingly wide spectrum of target cells, irrespective of transformation status, MHC background, or type of processing deficiency, was recognized by this T cell subset, complying with the conserved nature of Qa-1b. Target cell recognition depended on T cell receptor and Qa-1b interaction, and immunization with identified peptide epitopes demonstrated in vivo priming of CD8+ T cells. Our data reveal that Qa-1b, and most likely its human homologue human leukocyte antigen-E, is important for the defense against processing-deficient cells by displacing the monomorphic leader peptides, which relieves the inhibition through CD94/NKG2A on lymphocytes, and by presenting a novel repertoire of immunogenic peptides, which recruits a subset of cytotoxic CD8+ T cells.
非经典主要组织相容性复合体 (MHC) Qa-1b 容纳单态主导肽,并作为 CD94/NKG2 种系受体的配体发挥作用,CD94/NKG2 种系受体由自然杀伤细胞和 CD8+T 细胞表达。我们在这里描述的是,由于抗原加工途径受损,保守肽被新颖的、多样性惊人的肽库所取代。由于这些 Qa-1b 限制性 T 细胞在处理缺陷的肿瘤反应中占主导地位,因此,这种新型肽库代表了针对 CD8+T 细胞的免疫原性新抗原。出乎意料的是,广泛的靶细胞,无论转化状态、MHC 背景或处理缺陷的类型如何,都被这个 T 细胞亚群识别,这符合 Qa-1b 的保守性质。靶细胞的识别取决于 T 细胞受体和 Qa-1b 的相互作用,并且用鉴定的肽表位免疫接种证明了体内 CD8+T 细胞的初始激活。我们的数据表明,Qa-1b(很可能还有其人类同源物 HLA-E)对于通过置换单态主导肽来抵御处理缺陷细胞非常重要,这解除了 CD94/NKG2A 在淋巴细胞上的抑制作用,并呈现了新型的免疫原性肽库,招募了一群细胞毒性 CD8+T 细胞。